Author details

Full Name

Hanneke Schuitemaker

Affiliation

ORCID

Career Start Year

1988

Papers

321

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36927774	Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.		2023
36348617	Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.	Journal of Infectious Diseases	2023
37952003	Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen.		2023
37727795	Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.		2023
37029141	Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques.		2023
36949051	Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.		2023
35344464	Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6Â® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.	Human Vaccines and Immunotherapeutics	2022
35585080	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.	NPJ Vaccines	2022
36357712	Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.	Nat Microbiol	2022
36016151	Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels.	Vaccines	2022
35441174	Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.	medRxiv	2022
35689434	Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.	Immunological Reviews	2022
35429381	Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.	Journal of Infectious Diseases	2022
35667914	Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.	Vaccine	2022
36395347	Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer.	PLoS Pathog	2022
36450746	Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.	npj Vaccines	2022
36379957	Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.	npj Vaccines	2022
33400792	Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.	Journal of Infectious Diseases	2022
34973849	Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.	Vaccine	2022
34669426	The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.	Journal of Virology	2022
35191769	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.	Science Translational Medicine	2022
35013325	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.	npj Vaccines	2022
35197477	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice.	npj Vaccines	2022
35139271	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.	New England Journal of Medicine	2022
34705477	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern.	Science Translational Medicine	2021
33909009	Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.	Journal of Experimental Medicine	2021
33704352	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.	JAMA	2021
33692201	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection.	Journal of Virology	2021
33587687	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.	Ann Intern Med	2021
33741993	Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.	npj Vaccines	2021
33532782	Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques.		2021
33469218	Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.	Nature	2021
34161961	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.	Nature	2021
33676782	Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.	Vaccine	2021
34107529	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.	Nature	2021
34268527	Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.		2021
33882225	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.	New England Journal of Medicine	2021
34260834	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.	New England Journal of Medicine	2021
34133941	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.	Cell	2021
33440088	Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.	New England Journal of Medicine	2021
33175637	Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6Â® cell-line: a phase 1 randomized controlled trial in adults.	Human Vaccines and Immunotherapeutics	2021
32851411	Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.	Journal of Infectious Diseases	2021
34620860	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.	Nature Communications	2021
32999024	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.	Journal of Virology	2020
32320465	Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged â¿¥60 Years.	Journal of Infectious Diseases	2020
32235883	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.	Nature Medicine	2020
32884153	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.	Nat Med	2020
33083026	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.	npj Vaccines	2020
33077678	Prospects for a safe COVID-19 vaccine.	Science Translational Medicine	2020
32566260	Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice.	npj Vaccines	2020